Oregon is currently home to 1222 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Quantitative MRI Assessment of Breast Cancer Therapy Response
NCT05704062
Recruiting
The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \& Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very stro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Breast Cancer
Register for Updates
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492
Recruiting
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
01/07/2025
Locations: Velocity Clinical Research - Medford - PPDS, Medford, Oregon
Conditions: Cytomegalovirus
Register for Updates
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377
Recruiting
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Oregon Health & Science University-Knight Cardiovascular Institute, Portland, Oregon
Conditions: Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
Register for Updates
Descemet Endothelial Thickness Comparison Trial I
NCT05289661
Recruiting
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Fuchs
Register for Updates
Descemet Endothelial Thickness Comparison Trial II
NCT05275972
Recruiting
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Register for Updates
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT04594642
Recruiting
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/07/2025
Locations: Research Site, Portland, Oregon
Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Register for Updates
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT03699995
Recruiting
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/07/2025
Locations: Sancy Leachman, Portland, Oregon
Conditions: Cutaneous Melanoma, Melanocytic Nevus, Skin Carcinoma
Register for Updates
Evaluation of the Patellar LIFT System for Subjects with Patellofemoral Cartilage Degeneration
NCT06423300
Recruiting
The PELICAN study is a prospective, non randomized, dual arm, multi-center clinical study comparing clinical outcomes of subjects treated with the LIFT Implant System to subjects treated with Tibial Tubercle Osteotomy (TTO).
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
01/06/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Patellofemoral Osteoarthritis
Register for Updates
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Investigational Site #22, Portland, Oregon
Conditions: Atopic Dermatitis
Register for Updates
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Recruiting
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Oncology Associates of Oregon, P.C. /ID# 261816, Eugene, Oregon
Conditions: Follicular Lymphoma (FL)
Register for Updates
C-Protein in Fatigue and Aging
NCT05926219
Recruiting
This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/06/2025
Locations: University of Oregon, Eugene, Oregon
Conditions: Aging, Muscle Atrophy or Weakness, Sarcopenia in Elderly, Sarcopenia
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304
Recruiting
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
01/06/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates